Zofia Piotrowska

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer”.

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Cell Reports Medicine(2020)10.1016/j.xcrm.2020.100007

N/A

5.6DataRank · unranked

182 citations

Anna‐Leigh Brown, Jun S. Wei, Svetlana Pack, Christopher Trindade, Chul Kim +26 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3497

N/A

0.564DataRank · unranked

42 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz +16 more

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9014

N/A

0.373DataRank · unranked

11 citations

Mark Krailo, Sukhmani K. Padda, Susan Groshen, Heather A. Wakelee, Karen L. Reckamp +14 more

Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21112

N/A

0DataRank · unranked

0 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Anna Wurtz, Zofia Piotrowska, Andrew J. Piper‐Vallillo +13 more

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Nature(2023)10.1038/s41586-023-06303-1

N/A

0DataRank · unranked

148 citations

Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh +36 more

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.01.012

N/A

0DataRank · unranked

42 citations

So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances A. Shepherd, Chao Xu +52 more

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0466

N/A

0DataRank · unranked

32 citations

Catherine B. Meador, Xintao Qiu, Ji-Heui Seo, Matthew P. Davidsohn, Hunter Savignano +20 more

Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis

ESMO Open(2024)10.1016/j.esmoop.2024.103660

N/A

0DataRank · unranked

11 citations

B.Y. Yeap, Justin F. Gainor, Zofia Piotrowska

Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study

Lung Cancer(2024)10.1016/j.lungcan.2024.108003

N/A

0DataRank · unranked

8 citations

Alissa J. Cooper, Bruce E. Johnson, Justin F. Gainor, W. Marston Linehan, Lecia V. Sequist +6 more

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9513

N/A

0DataRank · unranked

104 citations

Yating Wang, Lecia V. Sequist, Suresh S. Ramalingam, Zofia Piotrowska

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Cancer Cell(2021)10.1016/j.ccell.2021.09.003

N/A

0DataRank · unranked

263 citations

Zofia Piotrowska, Patricia J. Hare, Huidong Chen, Hillary E. Mulvey, Aislinn Mayfield +23 more

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.010

N/A

0DataRank · unranked

42 citations

Zofia Piotrowska, Kevin Stirling, Stephen V. Liu, Mandeep K. Banwait, Kristen Cunanan +5 more